• Climb
    • Timmerman Traverse for LSC 2021
    • Everest Base Camp trek 2022
    • Kilimanjaro Climb
    • Mt. Everest
  • Speaking
  • About
    • Frontpoints
    • Podcast
    • Events
    • Internships
    • Team
      • David Shaywitz
      • Alex Harding
      • Stephanie Barnes
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Community
  • COVID-19
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Your Edge In Biotech.
  • Climb
    • Timmerman Traverse for LSC 2021
    • Everest Base Camp trek 2022
    • Kilimanjaro Climb
    • Mt. Everest
  • Speaking
  • About
    • Frontpoints
    • Podcast
    • Events
    • Internships
    • Team
      • David Shaywitz
      • Alex Harding
      • Stephanie Barnes
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Community
  • COVID-19
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
11
Feb
2015

Intelligent MDx, Maker of Molecular Diagnostics That Raised $40M, Shuts Down

/
Luke Timmerman
/
0
/
All, Diagnostics, Science
11 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
Feb
2015

FAQs About the Timmerman Report

/
Luke Timmerman
/
0
/
All, Cancer, Devices, Diagnostics, Drugs
11 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
Feb
2015

Cellular Dynamics Tracks Down ‘Superdonors’ for Cell Therapy

/
Luke Timmerman
/
0
/
All, Science, Strategy
09 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
6
Feb
2015

Q&A: Affymetrix Founder Stephen Fodor Resurfaces at Cellular Research

/
Luke Timmerman
/
1
/
All, Cancer, Devices, Genomics, Strategy
06 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Feb
2015

Former Dendreon CEO Lures Ex-Amgen Scientists to Immunotherapy Startup

/
Luke Timmerman
/
1
/
All, Cancer, Drugs
05 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
4
Feb
2015

Seattle Genetics Commercial Boss Leaves for President Gig at Bristol-Myers

/
Luke Timmerman
/
1
/
All, Cancer, Drugs, Strategy
04 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
4
Feb
2015

Third Rock’s Obesity Hopeful, Ember Therapeutics, Closes Down

/
Luke Timmerman
/
11
/
All, Drugs, Science, Strategy
04 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Feb
2015

The Merck Exodus: Where Are the Talented People Going?

/
Luke Timmerman
/
3
/
All, Drugs, FDA, Finance, Science, Strategy
02 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Feb
2015

Implications of the Biotech Boom on the Business and Science of R&D

/
Luke Timmerman
/
3
/
All, Drugs, Finance
02 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Feb
2015

Welcome to the Timmerman Report

/
Luke Timmerman
/
8
/
All
02 Feb 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 56 57 58

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

The Long Run Podcast

The Long Run Podcast

Sponsored By
Alpenglow

What Readers Are Saying

testimonial
testimonial
testimonial

View More Testimonials ➛

Twitter

Tweets by ldtimmerman Follow @ldtimmerman
© Copyright 2022, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder